Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects

Durlobactam (DUR; also known as ETX2514) is a novel β-lactamase inhibitor with broad activity against Ambler class A, C, and D β-lactamases. Addition of DUR to sulbactam (SUL) in vitro restores SUL activity against clinical isolates of Acinetobacter baumannii. The safety and pharmacokinetics (PK) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lickliter, Jason D., Lawrence, Kenneth, O’Donnell, John, Isaacs, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318034/
https://www.ncbi.nlm.nih.gov/pubmed/32284380
http://dx.doi.org/10.1128/AAC.00071-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318034/
https://www.ncbi.nlm.nih.gov/pubmed/32284380
http://dx.doi.org/10.1128/AAC.00071-20

Ejemplares similares